Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics, Inc. (WHWK)
:WHWK
WHWK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.21 - $3.81
Previous CloseN/A
VolumeN/A
Average Volume (3M)171.42K
Market Cap
$93.75M
Enterprise Value$251.46M
Total Cash (Recent Filing)$231.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)13.3
Beta0.36
Next Earnings
Aug 06, 2025EPS Estimate
0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.83
Shares Outstanding47,109,295
10 Day Avg. Volume112,722
30 Day Avg. Volume171,418
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.82
Price to Sales (P/S)0.00
P/FCF Ratio-5.77
Enterprise Value/Market Cap2.68
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit-19.65
Enterprise Value/Ebitda-0.98
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
Whitehawk Therapeutics News
Bulls Say, Bears Say
Bulls Say
Cash ReservesCash and equivalents will settle at ~$185MM following completion of transactions, providing runway.
Financial TransactionsThe company has now completed divestiture of Aadi Subsidiary to Kaken for $102MM on top of closing a $100MM PIPE.
Bears Say
ExpensesResearch and development expenses and selling, general, and administrative expenses greatly exceeded earlier estimates.
Financial PerformanceWhitehawk reported a net loss of $0.67 per share for 4Q24, significantly higher than previously estimated.
Ownership Overview
26.48%
Insiders
2.34%
Mutual Funds
4.58% Other Institutional Investors
64.86% Public Companies and Individual Investors
WHWK FAQ
What was Whitehawk Therapeutics, Inc.’s price range in the past 12 months?
Whitehawk Therapeutics, Inc. lowest stock price was $1.21 and its highest was $3.81 in the past 12 months.
What is Whitehawk Therapeutics, Inc.’s market cap?
Whitehawk Therapeutics, Inc.’s market cap is $93.75M.
When is Whitehawk Therapeutics, Inc.’s upcoming earnings report date?
Whitehawk Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 54 days.
How were Whitehawk Therapeutics, Inc.’s earnings last quarter?
Whitehawk Therapeutics, Inc. released its earnings results on May 08, 2025. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $2.29.
Is Whitehawk Therapeutics, Inc. overvalued?
According to Wall Street analysts Whitehawk Therapeutics, Inc.’s price is currently Overvalued.
Does Whitehawk Therapeutics, Inc. pay dividends?
Whitehawk Therapeutics, Inc. does not currently pay dividends.
What is Whitehawk Therapeutics, Inc.’s EPS estimate?
Whitehawk Therapeutics, Inc.’s EPS estimate is 0.49.
How many shares outstanding does Whitehawk Therapeutics, Inc. have?
Whitehawk Therapeutics, Inc. has 47,109,295 shares outstanding.
What happened to Whitehawk Therapeutics, Inc.’s price movement after its last earnings report?
Whitehawk Therapeutics, Inc. reported an EPS of $1.83 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went up 3.659%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics, Inc.?
Currently, no hedge funds are holding shares in WHWK
Whitehawk Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bearish
WHWK Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.60%
12-Months-Change
Fundamentals
Return on Equity
17.69%
Trailing 12-Months
Asset Growth
110.67%
Trailing 12-Months
Company Description
Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics (WHWK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer and other serious diseases. The company operates in the healthcare sector, specifically within the biotechnology industry, and is committed to advancing medical research to improve patient outcomes. Whitehawk Therapeutics leverages cutting-edge science and strategic collaborations to advance its pipeline of therapeutics through various stages of clinical development.
WHWK Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.Read More>